Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study

References

• Rozman C, Montserrat E. Chronic Lymphocytic Leukemia. N Engl J Med. 1995;333(16):1052–1057. doi:10.1056/NEJM1995101933316067675049
   PubMed Web of Science ®Google Scholar
• Ghia P, Ferreri AJM, Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2007;64(3):234–246. doi:10.1016/J.CRITREVONC.2007.04.00817544290
   PubMed Web of Science ®Google Scholar
• Pulte D, Castro FA, Jansen L, et al. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. J Hematol Oncol. 2016;9:28. doi:10.1186/s13045-016-0257-227000264
   PubMed Web of Science ®Google Scholar
• Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99(6):965–972. doi:10.3324/haematol.2013.09610724881042
   PubMed Web of Science ®Google Scholar
• Küppers R. B cells under influence: transformation of B cells by Epstein–Barr virus. Nat Rev Immunol. 2003;3(10):801–812. doi:10.1038/nri120114523386
   PubMed Web of Science ®Google Scholar
• De Roos AJ, Martinez-Maza O, Jerome KR, et al. Investigation of Epstein-Barr Virus as a Potential Cause of B-Cell Non-Hodgkin Lymphoma in a Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1747–1755. doi:10.1158/1055-9965.EPI-13-024023885038
   PubMed Web of Science ®Google Scholar
• Becker N, Falster MO, Vajdic CM, et al. Self-reported history of infections and the risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Int J Cancer. 2012;131(10):2342–2348. doi:10.1002/ijc.2743822266776
   PubMed Web of Science ®Google Scholar
• García-Barchino MJ, Sarasquete ME, Panizo C, et al. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol. 2018;245(1):61–73. doi:10.1002/path.506029464716
   PubMed Web of Science ®Google Scholar
• Grywalska E, Roliński J, Pasiarski M, et al. High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis. Pagano JS, ed. PLoS One. 2015;10(10):e0140178. doi:10.1371/journal.pone.014017826460692
   PubMed Web of Science ®Google Scholar
• McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–616. doi:10.1038/nature1446826123020
   PubMed Web of Science ®Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203–220. doi:10.1038/nrclinonc.2016.16827805626
   PubMed Web of Science ®Google Scholar
• Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–1618. doi:10.1158/1078-0432.CCR-11-194222271878
   PubMed Web of Science ®Google Scholar
• Grzywnowicz M, Zaleska J, Mertens D, et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. Lapteva N, ed. PLoS One. 2012;7(4):e35178. doi:10.1371/journal.pone.003517822532845
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–1621. doi:10.1182/blood-2012-09-45753123247726
   PubMed Web of Science ®Google Scholar
• Xerri L, Chetaille B, Seriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39(7):1050–1058. doi:10.1016/j.humpath.2007.11.01218479731
   PubMed Web of Science ®Google Scholar
• Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953–963. doi:10.3324/haematol.2012.07753723300177
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88(9):803–816. doi:10.1002/ajh.2349123720127
   PubMed Web of Science ®Google Scholar
• Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol. 2006;17(4):683–690. doi:10.1093/annonc/mdj12016524977
   PubMed Web of Science ®Google Scholar
• Kim HR, Ha S-J, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6(1):36956. doi:10.1038/srep3695627841362
   PubMedGoogle Scholar
• Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1). Proc Natl Acad Sci. 2018;115(43):E10119–E10126. doi:10.1073/pnas.180216611530297397
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri386226205583
   PubMed Web of Science ®Google Scholar
• Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. doi:10.3389/fimmu.2016.0055028018338
   PubMed Web of Science ®Google Scholar
• Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol. 2011;2011:451694. doi:10.1155/2011/45169421960736
   PubMedGoogle Scholar
• Hsu M-C, Hsiao J-R, Chang K-C, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23(10):1393–1403. doi:10.1038/modpathol.2010.13020657553
   PubMed Web of Science ®Google Scholar
• Igarashi T, Teramoto K, Ishida M, Hanaoka J, Daigo Y. Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open. 2016;1(4):e000083. doi:10.1136/esmoopen-2016-00008327843633
   PubMedGoogle Scholar
• Flavell KJ, Murray PG, Hodgkin’s disease and the Epstein-Barr virus. Mol Pathol. 2000;53(5):262–269. doi:10.1136/mp.53.5.26211091850
   PubMedGoogle Scholar
• Donato EM, Fernández-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:4583–4590. doi:10.2147/OTT.S14105330122950
   PubMed Web of Science ®Google Scholar